-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Calumet, Lowers Price Target to $21

Benzinga·05/14/2025 14:25:26
Listen to the news
Wells Fargo analyst Roger Read maintains Calumet (NASDAQ:CLMT) with a Overweight and lowers the price target from $23 to $21.